Eledon Pharmaceuticals Inc ELDN
News
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism